http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 14 Jul 2026 18:44:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BANC+OF+CALIFORNIA%2C+INC.+++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26769352.html si-local-file:///var/storage/secattach/20260714/26769352.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BANC+OF+CALIFORNIA%2C+INC.+++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26769352.html Tue, 14 Jul 2026 18:44:00 -0400 BANC O.30099367 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BANC+OF+CALIFORNIA%2C+INC.+++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26769352.html si-local-file:///var/storage/secattach/20260714/26769352.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BANC+OF+CALIFORNIA%2C+INC.+++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26769352.html Tue, 14 Jul 2026 18:44:00 -0400 BANC O.30099367 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BANC+OF+CALIFORNIA%2C+INC.++For%3A+Jul+08++Filed+by%3A+Rice+Joseph+J/26758178.html si-local-file:///var/storage/secattach/20260710/26758178.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BANC+OF+CALIFORNIA%2C+INC.++For%3A+Jul+08++Filed+by%3A+Rice+Joseph+J/26758178.html Fri, 10 Jul 2026 18:07:00 -0400 BANC O.30099367 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BANC+OF+CALIFORNIA%2C+INC.++For%3A+Jul+08++Filed+by%3A+Rice+Joseph+J/26758178.html si-local-file:///var/storage/secattach/20260710/26758178.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BANC+OF+CALIFORNIA%2C+INC.++For%3A+Jul+08++Filed+by%3A+Rice+Joseph+J/26758178.html Fri, 10 Jul 2026 18:07:00 -0400 BANC O.30099367 http://www.streetinsider.com/Press+Releases/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html <ul class="bwlistdisc"> <li> <i>Additional capital brings total raised to $150 million in a Series C financing <br></br> <br></br></i> </li> <li> <i>Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) <br></br> <br></br></i> </li> <li> <i>New Allotera name reflects the company’s focus on advancing allogeneic cell therapies for patients with aggressive blood cancers</i> </li> </ul> <p> ST. LOUIS--(BUSINESS WIRE)-- Allotera Therapeutics, Inc. (formerly Wugen, Inc.), a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for hematological malignancies, today announced the successful closing of a $35 million financing round comprising equity and venture debt. The company also http://www.streetinsider.com/Press+Releases/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html Wed, 08 Jul 2026 09:00:00 -0400 A.06822034 A.35146065 A.50216930 BANC O.20026344 O.30099367 O.55113340 O.55756447 http://www.streetinsider.com/Press+Releases/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html <ul class="bwlistdisc"> <li> <i>Additional capital brings total raised to $150 million in a Series C financing <br></br> <br></br></i> </li> <li> <i>Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) <br></br> <br></br></i> </li> <li> <i>New Allotera name reflects the company’s focus on advancing allogeneic cell therapies for patients with aggressive blood cancers</i> </li> </ul> <p> ST. LOUIS--(BUSINESS WIRE)-- Allotera Therapeutics, Inc. (formerly Wugen, Inc.), a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for hematological malignancies, today announced the successful closing of a $35 million financing round comprising equity and venture debt. The company also http://www.streetinsider.com/Press+Releases/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html Wed, 08 Jul 2026 09:00:00 -0400 A.06822034 A.35146065 A.50216930 BANC O.20026344 O.30099367 O.55113340 O.55756447 http://www.streetinsider.com/Press+Releases/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html <ul class="bwlistdisc"> <li> <i>Additional capital brings total raised to $150 million in a Series C financing <br></br> <br></br></i> </li> <li> <i>Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) <br></br> <br></br></i> </li> <li> <i>New Allotera name reflects the company’s focus on advancing allogeneic cell therapies for patients with aggressive blood cancers</i> </li> </ul> <p> ST. LOUIS--(BUSINESS WIRE)-- Allotera Therapeutics, Inc. (formerly Wugen, Inc.), a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for hematological malignancies, today announced the successful closing of a $35 million financing round comprising equity and venture debt. The company also http://www.streetinsider.com/Press+Releases/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html Wed, 08 Jul 2026 09:00:00 -0400 A.06822034 A.35146065 A.50216930 BANC O.20026344 O.30099367 O.55113340 O.55756447 http://www.streetinsider.com/Press+Releases/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html <ul class="bwlistdisc"> <li> <i>Additional capital brings total raised to $150 million in a Series C financing <br></br> <br></br></i> </li> <li> <i>Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) <br></br> <br></br></i> </li> <li> <i>New Allotera name reflects the company’s focus on advancing allogeneic cell therapies for patients with aggressive blood cancers</i> </li> </ul> <p> ST. LOUIS--(BUSINESS WIRE)-- Allotera Therapeutics, Inc. (formerly Wugen, Inc.), a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for hematological malignancies, today announced the successful closing of a $35 million financing round comprising equity and venture debt. The company also http://www.streetinsider.com/Press+Releases/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html Wed, 08 Jul 2026 09:00:00 -0400 A.06822034 A.35146065 A.50216930 BANC O.20026344 O.30099367 O.55113340 O.55756447 http://www.streetinsider.com/Press+Releases/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html <ul class="bwlistdisc"> <li> <i>Additional capital brings total raised to $150 million in a Series C financing <br></br> <br></br></i> </li> <li> <i>Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) <br></br> <br></br></i> </li> <li> <i>New Allotera name reflects the company’s focus on advancing allogeneic cell therapies for patients with aggressive blood cancers</i> </li> </ul> <p> ST. LOUIS--(BUSINESS WIRE)-- Allotera Therapeutics, Inc. (formerly Wugen, Inc.), a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for hematological malignancies, today announced the successful closing of a $35 million financing round comprising equity and venture debt. The company also http://www.streetinsider.com/Press+Releases/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html Wed, 08 Jul 2026 09:00:00 -0400 A.06822034 A.35146065 A.50216930 BANC O.20026344 O.30099367 O.55113340 O.55756447 http://www.streetinsider.com/Press+Releases/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html <ul class="bwlistdisc"> <li> <i>Additional capital brings total raised to $150 million in a Series C financing <br></br> <br></br></i> </li> <li> <i>Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) <br></br> <br></br></i> </li> <li> <i>New Allotera name reflects the company’s focus on advancing allogeneic cell therapies for patients with aggressive blood cancers</i> </li> </ul> <p> ST. LOUIS--(BUSINESS WIRE)-- Allotera Therapeutics, Inc. (formerly Wugen, Inc.), a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for hematological malignancies, today announced the successful closing of a $35 million financing round comprising equity and venture debt. The company also http://www.streetinsider.com/Press+Releases/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html Wed, 08 Jul 2026 09:00:00 -0400 A.06822034 A.35146065 A.50216930 BANC O.20026344 O.30099367 O.55113340 O.55756447 http://www.streetinsider.com/Press+Releases/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html <ul class="bwlistdisc"> <li> <i>Additional capital brings total raised to $150 million in a Series C financing <br></br> <br></br></i> </li> <li> <i>Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) <br></br> <br></br></i> </li> <li> <i>New Allotera name reflects the company’s focus on advancing allogeneic cell therapies for patients with aggressive blood cancers</i> </li> </ul> <p> ST. LOUIS--(BUSINESS WIRE)-- Allotera Therapeutics, Inc. (formerly Wugen, Inc.), a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for hematological malignancies, today announced the successful closing of a $35 million financing round comprising equity and venture debt. The company also http://www.streetinsider.com/Press+Releases/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html Wed, 08 Jul 2026 09:00:00 -0400 A.06822034 A.35146065 A.50216930 BANC O.20026344 O.30099367 O.55113340 O.55756447 http://www.streetinsider.com/Press+Releases/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html <ul class="bwlistdisc"> <li> <i>Additional capital brings total raised to $150 million in a Series C financing <br></br> <br></br></i> </li> <li> <i>Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) <br></br> <br></br></i> </li> <li> <i>New Allotera name reflects the company’s focus on advancing allogeneic cell therapies for patients with aggressive blood cancers</i> </li> </ul> <p> ST. LOUIS--(BUSINESS WIRE)-- Allotera Therapeutics, Inc. (formerly Wugen, Inc.), a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for hematological malignancies, today announced the successful closing of a $35 million financing round comprising equity and venture debt. The company also http://www.streetinsider.com/Press+Releases/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html Wed, 08 Jul 2026 09:00:00 -0400 A.06822034 A.35146065 A.50216930 BANC O.20026344 O.30099367 O.55113340 O.55756447 http://www.streetinsider.com/Business+Wire/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html <ul class="bwlistdisc"> <li> <i>Additional capital brings total raised to $150 million in a Series C financing <br></br> <br></br></i> </li> <li> <i>Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) <br></br> <br></br></i> </li> <li> <i>New Allotera name reflects the company’s focus on advancing allogeneic cell therapies for patients with aggressive blood cancers</i> </li> </ul> <p> ST. LOUIS--(BUSINESS WIRE)-- Allotera Therapeutics, Inc. (formerly Wugen, Inc.), a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for hematological malignancies, today announced the successful closing of a $35 million financing round comprising equity and venture debt. The company also http://www.streetinsider.com/Business+Wire/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html Wed, 08 Jul 2026 09:00:00 -0400 A.06822034 A.35146065 A.50216930 BANC O.20026344 O.30099367 O.55113340 O.55756447 http://www.streetinsider.com/Business+Wire/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html <ul class="bwlistdisc"> <li> <i>Additional capital brings total raised to $150 million in a Series C financing <br></br> <br></br></i> </li> <li> <i>Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) <br></br> <br></br></i> </li> <li> <i>New Allotera name reflects the company’s focus on advancing allogeneic cell therapies for patients with aggressive blood cancers</i> </li> </ul> <p> ST. LOUIS--(BUSINESS WIRE)-- Allotera Therapeutics, Inc. (formerly Wugen, Inc.), a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for hematological malignancies, today announced the successful closing of a $35 million financing round comprising equity and venture debt. The company also http://www.streetinsider.com/Business+Wire/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html Wed, 08 Jul 2026 09:00:00 -0400 A.06822034 A.35146065 A.50216930 BANC O.20026344 O.30099367 O.55113340 O.55756447 http://www.streetinsider.com/Business+Wire/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html <ul class="bwlistdisc"> <li> <i>Additional capital brings total raised to $150 million in a Series C financing <br></br> <br></br></i> </li> <li> <i>Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) <br></br> <br></br></i> </li> <li> <i>New Allotera name reflects the company’s focus on advancing allogeneic cell therapies for patients with aggressive blood cancers</i> </li> </ul> <p> ST. LOUIS--(BUSINESS WIRE)-- Allotera Therapeutics, Inc. (formerly Wugen, Inc.), a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for hematological malignancies, today announced the successful closing of a $35 million financing round comprising equity and venture debt. The company also http://www.streetinsider.com/Business+Wire/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html Wed, 08 Jul 2026 09:00:00 -0400 A.06822034 A.35146065 A.50216930 BANC O.20026344 O.30099367 O.55113340 O.55756447 http://www.streetinsider.com/Business+Wire/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html <ul class="bwlistdisc"> <li> <i>Additional capital brings total raised to $150 million in a Series C financing <br></br> <br></br></i> </li> <li> <i>Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) <br></br> <br></br></i> </li> <li> <i>New Allotera name reflects the company’s focus on advancing allogeneic cell therapies for patients with aggressive blood cancers</i> </li> </ul> <p> ST. LOUIS--(BUSINESS WIRE)-- Allotera Therapeutics, Inc. (formerly Wugen, Inc.), a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for hematological malignancies, today announced the successful closing of a $35 million financing round comprising equity and venture debt. The company also http://www.streetinsider.com/Business+Wire/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html Wed, 08 Jul 2026 09:00:00 -0400 A.06822034 A.35146065 A.50216930 BANC O.20026344 O.30099367 O.55113340 O.55756447 http://www.streetinsider.com/Business+Wire/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html <ul class="bwlistdisc"> <li> <i>Additional capital brings total raised to $150 million in a Series C financing <br></br> <br></br></i> </li> <li> <i>Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) <br></br> <br></br></i> </li> <li> <i>New Allotera name reflects the company’s focus on advancing allogeneic cell therapies for patients with aggressive blood cancers</i> </li> </ul> <p> ST. LOUIS--(BUSINESS WIRE)-- Allotera Therapeutics, Inc. (formerly Wugen, Inc.), a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for hematological malignancies, today announced the successful closing of a $35 million financing round comprising equity and venture debt. The company also http://www.streetinsider.com/Business+Wire/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html Wed, 08 Jul 2026 09:00:00 -0400 A.06822034 A.35146065 A.50216930 BANC O.20026344 O.30099367 O.55113340 O.55756447 http://www.streetinsider.com/Business+Wire/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html <ul class="bwlistdisc"> <li> <i>Additional capital brings total raised to $150 million in a Series C financing <br></br> <br></br></i> </li> <li> <i>Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) <br></br> <br></br></i> </li> <li> <i>New Allotera name reflects the company’s focus on advancing allogeneic cell therapies for patients with aggressive blood cancers</i> </li> </ul> <p> ST. LOUIS--(BUSINESS WIRE)-- Allotera Therapeutics, Inc. (formerly Wugen, Inc.), a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for hematological malignancies, today announced the successful closing of a $35 million financing round comprising equity and venture debt. The company also http://www.streetinsider.com/Business+Wire/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html Wed, 08 Jul 2026 09:00:00 -0400 A.06822034 A.35146065 A.50216930 BANC O.20026344 O.30099367 O.55113340 O.55756447 http://www.streetinsider.com/Business+Wire/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html <ul class="bwlistdisc"> <li> <i>Additional capital brings total raised to $150 million in a Series C financing <br></br> <br></br></i> </li> <li> <i>Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) <br></br> <br></br></i> </li> <li> <i>New Allotera name reflects the company’s focus on advancing allogeneic cell therapies for patients with aggressive blood cancers</i> </li> </ul> <p> ST. LOUIS--(BUSINESS WIRE)-- Allotera Therapeutics, Inc. (formerly Wugen, Inc.), a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for hematological malignancies, today announced the successful closing of a $35 million financing round comprising equity and venture debt. The company also http://www.streetinsider.com/Business+Wire/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html Wed, 08 Jul 2026 09:00:00 -0400 A.06822034 A.35146065 A.50216930 BANC O.20026344 O.30099367 O.55113340 O.55756447 http://www.streetinsider.com/Business+Wire/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html <ul class="bwlistdisc"> <li> <i>Additional capital brings total raised to $150 million in a Series C financing <br></br> <br></br></i> </li> <li> <i>Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) <br></br> <br></br></i> </li> <li> <i>New Allotera name reflects the company’s focus on advancing allogeneic cell therapies for patients with aggressive blood cancers</i> </li> </ul> <p> ST. LOUIS--(BUSINESS WIRE)-- Allotera Therapeutics, Inc. (formerly Wugen, Inc.), a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for hematological malignancies, today announced the successful closing of a $35 million financing round comprising equity and venture debt. The company also http://www.streetinsider.com/Business+Wire/Allotera+Therapeutics+%28Formerly+Wugen%29+Closes+%2435+Million+Financing+to+Advance+Off-the-Shelf+CAR-T+Therapies+for+T-Cell+Cancers/26745087.html Wed, 08 Jul 2026 09:00:00 -0400 A.06822034 A.35146065 A.50216930 BANC O.20026344 O.30099367 O.55113340 O.55756447 http://www.streetinsider.com/Analyst+PT+Change/Banc+of+California+%28BANC%29+PT+Raised+to+%2423+at+Wells+Fargo/26732390.html Wells Fargo analyst Chris Spahr raised the price target on Banc of California (NYSE: BANC) to $23.00 (from $22.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Banc+of+California+%28BANC%29+PT+Raised+to+%2423+at+Wells+Fargo/26732390.html Mon, 06 Jul 2026 06:27:42 -0400 BANC http://www.streetinsider.com/Analyst+PT+Change/Banc+of+California+%28BANC%29+PT+Raised+to+%2424+at+JPMorgan/26717146.html JPMorgan analyst Anthony Elian raised the price target on Banc of California (NYSE: BANC) to $24.00 (from $22.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Banc+of+California+%28BANC%29+PT+Raised+to+%2424+at+JPMorgan/26717146.html Wed, 01 Jul 2026 08:01:15 -0400 BANC http://www.streetinsider.com/SEC+Filings/Form++144++++++++BANC+OF+CALIFORNIA%2C+INC.+++++++++++++++Filed+by%3A+PL+Capital+Advisors%2C+LLC/26637309.html si-local-file:///var/storage/secattach/20260611/26637309.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BANC+OF+CALIFORNIA%2C+INC.+++++++++++++++Filed+by%3A+PL+Capital+Advisors%2C+LLC/26637309.html Thu, 11 Jun 2026 21:33:00 -0400 BANC O.30099367 http://www.streetinsider.com/SEC+Filings/Form++144++++++++BANC+OF+CALIFORNIA%2C+INC.+++++++++++++++Filed+by%3A+PL+Capital+Advisors%2C+LLC/26637309.html si-local-file:///var/storage/secattach/20260611/26637309.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BANC+OF+CALIFORNIA%2C+INC.+++++++++++++++Filed+by%3A+PL+Capital+Advisors%2C+LLC/26637309.html Thu, 11 Jun 2026 21:33:00 -0400 BANC O.30099367 http://www.streetinsider.com/SEC+Filings/Form++144++++++++BANC+OF+CALIFORNIA%2C+INC.+++++++++++++++Filed+by%3A+WARBURG+PINCUS+LLC/26576574.html si-local-file:///var/storage/secattach/20260529/26576574.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BANC+OF+CALIFORNIA%2C+INC.+++++++++++++++Filed+by%3A+WARBURG+PINCUS+LLC/26576574.html Fri, 29 May 2026 17:18:00 -0400 BANC O.30099367